A Phase 1, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPL84
Latest Information Update: 31 Jan 2024
At a glance
- Drugs SPL84-23 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors SpliSense
- 11 Jan 2024 Status changed from recruiting to completed.
- 06 Sep 2023 According to a SpliSense media release, encouraging Phase 1 clinical trial results published in Nucleic Acid Therapeutics.
- 06 Sep 2023 Results from phase 1 portion (n=32; healthy male volunteers) published in a SpliSense media release.